Ceftaroline for Methicillin-Resistant Staphylococcus aureus Endovascular Infection

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) endovascular infections present significant mortality risks.
• First-line vancomycin use is increasingly associated with clinical failures and toxicity, necessitating alternative treatments.
• Ceftaroline, a beta-lactam antibiotic, exhibits anti-MRSA activity, making it a potential therapeutic option.

Purpose of the Study:

• To review the efficacy and tolerability of ceftaroline for off-label treatment of MRSA endovascular infections.
• To analyze studies published between 2017 and 2025 evaluating ceftaroline's role in managing these serious infections.

Main Methods:

• A narrative review of scientific literature from 2017 to 2025.
• Inclusion of diverse study types: 1 randomized controlled trial, 17 retrospective cohort studies, 4 case series, and 1 meta-analysis.
• Analysis focused on treatment outcomes, failure rates, and adverse events associated with ceftaroline.

Main Results:

• Monotherapy with ceftaroline demonstrated failure rates comparable to vancomycin and daptomycin.
• Combination therapy involving ceftaroline with vancomycin or daptomycin showed efficacy and tolerability in high-risk MRSA bacteremia cases.
• Ceftaroline emerged as a potential strategy for severe MRSA endovascular infections.

Conclusions:

• Current evidence suggests ceftaroline is a valuable antibiotic option for MRSA endovascular infections, particularly in combination therapy.
• While ceftaroline is not yet a mainstay treatment, it represents a significant therapeutic alternative for complex cases.
• Further high-level evidence is required to solidify ceftaroline's role in the standard treatment guidelines for MRSA endovascular infections.